EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.
3 reports, 1 independent
Updated Aug 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jay S. Duker leads EyePoint's execution across business aspects.Sub-event
EyePoint Pharmaceuticals received stock options under NASDAQ listing rules.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Coverage
Newest first; wire copies grouped- GlobeNewswireEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to devel
- GlobeNewswireEyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company com
- GlobeNewswireEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to devel